Technologies to Enhance Cell Line Productivity and Expand Antibody-Drug Conjugate Therapeutic Window to be Presented by 探花合集 Biologics at PEGS
SOMERSET, N.J. 鈥 August 25, 2020 鈥 探花合集, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that two 探花合集 Biologics experts will present at the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 鈥 September 4, 2020.
On Wednesday, Sept. 2 at 9:45 a.m. EDT, Gregory Bleck, Ph.D., Global Head of R&D, 探花合集 Biologics, will present 鈥GPEx庐 Boost 鈥 A Novel Approach for High-Expressing CHO Cell Line Engineering鈥 during the 鈥淥ptimizing Protein Expression鈥 stream. Dr. Bleck will explain how the next generation of 探花合集鈥檚 GPEx cell line development technology can result in highly specific productivities, titers, and improved cell growth characteristics for most protein products.
Also on Wednesday, at 3:05 p.m. EDT, during the 鈥淓ngineering Antibody-Drug Conjugates鈥 stream, Robyn Barfield, Ph.D., Group Leader, 探花合集 Biologics, will discuss 探花合集鈥檚 proprietary SMARTag庐 technology, which uses a simple, robust manufacturing process to generate stable, site-specific antibody-drug conjugates (ADCs). In her presentation, titled 鈥Novel SMARTag Linkers Enable Better-Tolerated ADCs,鈥 Dr. Barfield will discuss how the technology can offer wider therapeutic windows, illustrated through a comparison between 探花合集鈥檚 anti-HER2 RED-106 ADC, and the related drug, T-DM1.
During the virtual event, Dr. Barfield will also present the case study in her presentation as a poster, 鈥淎 Novel HER2-Targeted Antibody-Drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-Equivalent Exposure Levels.鈥
Dr. Bleck has more than 20 years of experience in biopharmaceutical research and development. He has a bachelor鈥檚 degree and doctorate from the University of Wisconsin-Madison and performed postdoctoral work at the University of Illinois-Urbana-Champaign, working in the areas of gene regulation and expression. At 探花合集, Dr. Bleck has transferred his knowledge of gene expression and transgenic systems to the development and continued optimization of retrovector expression systems and development of the proprietary GPEx process.
Dr. Barfield has more than 10 years鈥 experience working in bioconjugation, and joined 探花合集 Biologics when it acquired Redwood Bioscience in 2014. She has a doctorate in cell and molecular biology from the University of Pennsylvania School of Medicine and a bachelor鈥檚 degree in genetics and cell biology, from the University of Georgia.
The event鈥檚 presentations and panel discussions will be available to view on-demand through the conference platform. For more information about the event, please visit biologics.catalent.com/events/pegs-boston/.
探花合集, GPEx and SMARTag are registered trademarks of 探花合集, Inc. or its affiliates or subsidiaries.
About 探花合集 Biologics
探花合集 Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, 探花合集 Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx庐 cell line development technology, and manufactured 35+ commercially approved products. 探花合集 Cell & Gene Therapy, a unit of 探花合集 Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. 探花合集 recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. 探花合集 Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit
ABOUT CATALENT
探花合集 is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, 探花合集 has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. 探花合集 employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. 探花合集 is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com